Sinopharm (company)

This article is about the pharmaceutical company. For the COVID-19 vaccine that it developed, see Sinopharm BIBP COVID-19 vaccine.

For other uses, see Sinopharm (disambiguation).

"Sinopharm" redirects here. Not to be confused with Sinovac Biotech.

39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401

China National Pharmaceutical Group Corporation

Headquarters
Trade name	Sinopharm
Type	state-owned enterprise
Founded	November 26, 1998
Headquarters	20 Zhichun Road, Haidian District, Beijing , China
Area served	China, exported worldwide
Key people	Liu Jingzhen (Chairman & Chinese Communist Party Committee Secretary)^[1]^[2]
Revenue	CN¥247.110 billion (2014)
Operating income	CN¥8.758 billion (2014)
Net income	CN¥2.705 billion (2014)
Total assets	CN¥199.192 billion (2014)
Total equity	CN¥31.944 billion (2014)
Owner	Chinese central government (100%)
Parent	SASAC of the State Council
Subsidiaries	Sinopharm Industrial Investment (51%) → Sinopharm Group (56.79%) Trad. Chinese Medicine (37.59%) Shyndec Pharma. (41.62%) China National Biotec Group (95%) → Tiantan Biological (53.30%)
Chinese name
Simplified Chinese	中国医药集团总公司
Traditional Chinese	中國醫藥集團總公司
Transcriptions Standard Mandarin Hanyu Pinyin Zhōngguó yīyào jítuán zǒng gōngsī
short Chinese name
Simplified Chinese	国药集团
Traditional Chinese	國藥集團
Transcriptions Standard Mandarin Hanyu Pinyin Guóyào jítuán
Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards^[3]

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),^[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.^[5]

Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.^[6]

History

Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).^{[citation needed]}

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.^[7]

Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.^[8]

COVID-19 vaccines

Main articles: Sinopharm BIBP COVID-19 vaccine, Sinopharm WIBP COVID-19 vaccine, and Sinopharm CNBG COVID-19 vaccine

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,^[9] the Sinopharm COVID-19 vaccine,^[10] or BIBP vaccine,^[10][11][12] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.^[13] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.^[14]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).^[15] In December 2020, the UAE previously announced interim results showing 86% efficacy.^[16] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.^[17]

BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,^[18][19][20] Africa,^[21][22][23] South America,^[24][25][26] and Europe.^[27][28][29] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.^[30] On 7 May 2021, the World Health Organization approved the vaccine for emergency use^[31] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.^[32]

The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.^{[citation needed]}

See also

• CanSino Biologics
• Sinovac

References

1. (in Chinese). Sinopharm. Archived from the original on 2022-09-08. Retrieved 2021-08-24.
2. "Liu Jingzhen". Bloomberg.
3. "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
4. "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
5. "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
6. "Global 500".
7. "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
8. "Pfizer signs strategic cooperation pact with China's Sinopharm". Reuters. 2023-04-13. Retrieved 2023-11-08.
9. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
10. "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
11. Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
12. Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
13. Liu, Roxanne; Munroe, Tony (2020-11-19). Sarkar, Himani (ed.). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Beijing. Retrieved 2023-01-19.
14. Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
15. Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
16. "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 2020-12-13.
17. "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
18. Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
19. Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
20. Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
21. Waly, Mohamed; Eltahir, Nafisa (2021-01-24). Richardson, Alex (ed.). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Cairo. Retrieved 2023-01-19.
22. Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
23. "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
24. "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
25. Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
26. "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
27. "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 2021-01-21.
28. "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
29. "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
30. "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
31. Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
32. "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.

External links

• Official website